Cantor Fitzgerald Predicts Organogenesis FY2026 Earnings

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Equities researchers at Cantor Fitzgerald issued their FY2026 EPS estimates for Organogenesis in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will earn $0.16 per share for the year. The consensus estimate for Organogenesis’ current full-year earnings is ($0.07) per share.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). The business had revenue of $86.69 million during the quarter, compared to analysts’ expectations of $90.77 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%.

Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 5th.

Organogenesis Price Performance

ORGO stock opened at $3.17 on Wednesday. Organogenesis has a 12 month low of $2.28 and a 12 month high of $6.71. The firm has a market capitalization of $402.13 million, a P/E ratio of -52.83 and a beta of 1.63. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $3.77 and a 200-day moving average of $3.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Merit Financial Group LLC bought a new stake in Organogenesis in the first quarter worth $45,000. Virtu Financial LLC purchased a new position in shares of Organogenesis during the fourth quarter valued at $38,000. Victory Capital Management Inc. purchased a new position in Organogenesis in the first quarter valued at about $67,000. OMERS ADMINISTRATION Corp purchased a new position in Organogenesis in the first quarter valued at about $77,000. Finally, Ieq Capital LLC purchased a new stake in shares of Organogenesis during the first quarter worth about $79,000. 49.57% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Organogenesis

In other news, insider Lori Freedman bought 9,022 shares of Organogenesis stock in a transaction that occurred on Friday, June 6th. The stock was bought at an average cost of $2.99 per share, with a total value of $26,975.78. Following the acquisition, the insider now owns 846,459 shares of the company’s stock, valued at $2,530,912.41. The trade was a 1.08% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have purchased 252,264 shares of company stock worth $725,732. Company insiders own 33.00% of the company’s stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.